Evidence map›Paper›PMID 27358899›Full record

ArticleStem cell investigation2016

CD34(+) therapy-related acute promyelocytic leukemia in a patient previously treated for breast cancer.

John Savooji, Fouzia Shakil, Humayun Islam, Delong Liu, Karen Seiter

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell investigation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

John Savooji1 Department of Medicine, New York Medical College, Valhalla, NY, USA ; 2 Department of Pathology, Westchester Medical Center, Valhalla, NY, USA.
Fouzia Shakil1 Department of Medicine, New York Medical College, Valhalla, NY, USA ; 2 Department of Pathology, Westchester Medical Center, Valhalla, NY, USA.
Humayun Islam1 Department of Medicine, New York Medical College, Valhalla, NY, USA ; 2 Department of Pathology, Westchester Medical Center, Valhalla, NY, USA.
Delong Liu1 Department of Medicine, New York Medical College, Valhalla, NY, USA ; 2 Department of Pathology, Westchester Medical Center, Valhalla, NY, USA.
Karen Seiter1 Department of Medicine, New York Medical College, Valhalla, NY, USA ; 2 Department of Pathology, Westchester Medical Center, Valhalla, NY, USA.
New York Medical College · USWestchester Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapy-related acute myeloid leukemia (AML) is a long term complication of chemotherapy for a variety of cancers. In most cases, the marrow demonstrates high risk cytogenetics and the prognosis is poor. In a minority of patients "good risk" cytogenetics, including t(15;17)(q22;q12), are seen and the patient's prognosis is similar to those who have de novo disease. Currently we present a patient who developed therapy-related acute promyelocytic leukemia (APL) after chemoradiotherapy for breast cancer. This case was especially atypical because the leukemic cells were CD34(+), which is an unusual immunophenotype for APL. Recognition that this patient had APL, rather than the more common therapy-related MDS or AML, was imperative to initiate chemotherapy in a timely manner.

Indexed as

Acute promyelocytic leukemia (APL)breast cancerCD34+therapy-related leukemia

Identifiers

PMID27358899
PMCPMC4923647
OpenAlexW2340191535

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.